Innovate U.K. and the Medical Research Council have awarded over $47.1 million in new funding through the Biomedical Catalyst, part of the U.K. government’s life sciences strategy.
Twenty-nine companies and universities in the U.K. now have funding to tackle healthcare challenges ranging from cancer to childbirth complications. Projects supported include:
pH paper to prevent fatality through incorrect placement of feeding tubes
dressings with embedded clotting agents, which can be left in the body
ozone-based generator to decontaminate medical equipment
drugs to reduce swelling and pain caused by rheumatoid arthritis
a sensor hat to monitor newborn babies requiring resuscitation
new gene therapy to tackle nerve and muscle degeneration caused by Huntington’s disease
a revolutionary gamma camera to help diagnose and treat more cancers
a bio-engineered scaffold to repair injured tendons.
This follows 23 separate feasibility awards, totaling over $4.7 million, made earlier in 2014. It brings total investment via the Biomedical Catalyst to over $314 million since it was launched in 2012. It has leveraged a further $157 million in industry co-commitment and supported innovation from some 250 SME companies and universities.
